Previous study showed that higher expression level of TIGIT in patients after allo‐HSCT was associated with a decreased incidence of acute GVHD.[28] In GVHD mouse models, TIGIT‐Fc‐treated mice had alleviated GVHD symptom occurrence and delayed mortality compared to that in isotype control group mice.[29] Taken together, SOCS1‐mediated increased expression of TIGIT in primary T cells suggests that high expression level of SOCS1 decreased GVHD occurrence might through upregulating TIGIT in patients after allo‐HSCT. The gene discussed is SOCS1; the disease is graft versus host disease.